EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A Dual Prevention Pill for HIV & Pregnancy Prevention: A Pilot Study Among Adolescent Girls and Young Women in Zimbabwe

Nyaradzo M Mgodi, J Brady Burnett-Zieman, Caroline Murombedzi, Adlight Dandadzi, Vanessa Gatsi, Petina Musara, Sheu Matimbira, Gamuchirai Mavemwa, Jane Jambaya, Tinashe Chidemo, Marlena Plagianos, Lisa B Haddad und 3 weitere

AIDS and Behavior · 2026

DOI: 10.1007/s10461-025-04909-2 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift AIDS and Behavior, 2026. Verfasst von Nyaradzo M Mgodi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Heath Sciences, Clinical Trials Research Centre, University of Zimbabwe, 15 Phillips Avenue, Belgravia, Harare, Zimbabwe. nmg…. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIMH NIH HHS, Children's Investment Fund Foundation, National Institute of Mental Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adolescent girls and young women (AGYW) in sub-Saharan Africa are at risk for HIV/unintended pregnancy. Adherence and continuation to effective oral pre-exposure prophylaxis (PrEP) are limited in AGYW. We hypothesized that an over-encapsulated dual prevention pill (DPP) combining PrEP + oral contraceptive (OC) would be preferred, acceptable, and improve adherence compared to PrEP alone. We randomized HIV-uninfected, 16-24 year-olds 1:1 to use DPP or 2-pill regimen (2PR -PrEP and OCs separately) for three 28-day cycles each. We compared preference for DPP vs. 2PR (exact binomial test) and regimen effects on four acceptability domains: use attributes, product attributes, side effects, impact on sex (Wilcoxon signed-rank tests). Adherence was compared by regimen and sequence (mixed-effects logistic regression) using self-report, pill-count, tenofovir-diphosphate levels in dried blood spots (DBS), indicating ≥ 4 doses per week(≥ 500 fmol/punch at Month 1 and ≥ 700 fmol/punch at Months 2-6). 26/30 participants (mean age 19.4years) completed the study (Nov 2022-Sept 2023). 62% preferred DPP, 38% 2PR (p = 0.24). Most rated both regimens as acceptable, with no differences between them (all p > 0.05). Adherence was high by self-report (98%) and pill-count (97%), but low based on DBS results (DPP: mean 392 fmol/punch, 2PR: mean 384 fmol/punch); with only 10% consistently adherent. There was no difference in adherence by regimen, though odds were higher in period 1 vs. 2 (AOR 3.7; 95% CI 1.10-12.8). Both regimens were safe; 2 pregnancies occurred during the DPP regimen, with no HIV seroconversions. No significant differences in preference, acceptability, and adherence between DPP and 2PR were found in this study. Adherence was low and waned over time. A larger study with a smaller co-formulated DPP may better inform its impact on HIV and pregnancy prevention.The study has been registered at ClinicalTrials.gov Identifier NCT04778514.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisAnti-HIV AgentsHumansFemaleAdolescentPregnancyPilot ProjectsYoung AdultZimbabweMedication AdherenceTenofovirAdenineOrganophosphates

Stichwörter der Autor:innen

Adolescent girls and young womenDual prevention pillHIV preventionMultipurpose prevention technologiesOral contraceptivePre-exposure prophylaxis

Substanzen

Anti-HIV AgentsTenofovirtenofovir diphosphateAdenineOrganophosphates

Autor:innen und Institutionen

  • Faculty of Medicine and Heath Sciences, Clinical Trials Research Centre, University of Zimbabwe, 15 Phillips Avenue, Belgravia, Harare, Zimbabwe. nmgodi@uz-ctrc.org.
  • Population Council, Center for Biomedical Research, New York, NY, USA.
  • Faculty of Medicine and Heath Sciences, Clinical Trials Research Centre, University of Zimbabwe, 15 Phillips Avenue, Belgravia, Harare, Zimbabwe.
  • Population Council, Washington, DC, USA.

Förderung

  • NIMH NIH HHS
  • Children's Investment Fund Foundation
  • National Institute of Mental Health

Zitieren

APA

Mgodi, N. M., Burnett-Zieman, J. B., Murombedzi, C., Dandadzi, A., Gatsi, V., Musara, P., Matimbira, S., Mavemwa, G., Jambaya, J., Chidemo, T., Plagianos, M., Haddad, L. B., Bruce, I. V., Mathur, S., & Friedland, B. A. (2026). A Dual Prevention Pill for HIV & Pregnancy Prevention: A Pilot Study Among Adolescent Girls and Young Women in Zimbabwe. AIDS and Behavior. https://doi.org/10.1007/s10461-025-04909-2

Vancouver

Mgodi NM, Burnett-Zieman JB, Murombedzi C, Dandadzi A, Gatsi V, Musara P, et al. A Dual Prevention Pill for HIV & Pregnancy Prevention: A Pilot Study Among Adolescent Girls and Young Women in Zimbabwe. AIDS and Behavior. 2026. doi:10.1007/s10461-025-04909-2

BibTeX
@article{Mgodi2026,
  author = {Mgodi, Nyaradzo M and Burnett-Zieman, J Brady and Murombedzi, Caroline and Dandadzi, Adlight and Gatsi, Vanessa and Musara, Petina and Matimbira, Sheu and Mavemwa, Gamuchirai and Jambaya, Jane and Chidemo, Tinashe and Plagianos, Marlena and Haddad, Lisa B and Bruce, Irene V and Mathur, Sanyukta and Friedland, Barbara A},
  title = {A Dual Prevention Pill for HIV & Pregnancy Prevention: A Pilot Study Among Adolescent Girls and Young Women in Zimbabwe},
  journal = {AIDS and Behavior},
  year = {2026},
  doi = {10.1007/s10461-025-04909-2}
}
Kostenlos starten →